Browse Studies — Arctuva

Phase 1

A Phase I Study of Metronomic Temozolomide With Abexinostat (PCI-24781) for Patients With Recurrent High Grade Glioma

Glioblastoma (GBM), WHO grade IV glioma, represents the majority of adult malignant primary brain tumors, with an incidence of 2-3 per 100,000 person-years. Th…

Recurrent High Grade GliomaAnaplastic AstrocytomaAnaplastic Oligodendroglioma+2 more

Estimated

~$10 – $6,250

University of NebraskaNCT05698524

Phase 1

The PuMP Trial: "A Multistage Phase 1 Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of the Oncolytic HSV1 MVR-C5252 in Patients With Recurrent High-Grade Glioma"

This is a Phase 1 open label study designed to assess the safety and tolerability of the oncolytic herpes simplex virus 1 (oHSV1) study drug, MVR-C5252, admini…

Recurrent High Grade Glioma

Estimated

~$10 – $6,250

Duke UniversityNCT06126744

Phase 1

Phase I Trial: CD200 Activation Receptor Ligand (CD200AR-L) and Allogeneic Tumor Lysate Vaccine Immunotherapy With Adjuvant Reirradiation for Recurrent High-Grade Glioma and Newly Diagnosed Diffuse Midline Glioma/Diffuse Intrinsic Pontine Glioma in Children and Young Adults

This is a single center Phase I study of a new adjuvant CD200 activation receptor ligand, CD200AR-L, in combination with imiquimod and GBM6-AD vaccine to treat…

Diffuse Midline Glioma, H3 K27M-MutantRecurrent High Grade Glioma

Estimated

~$10 – $8,750

OX2 TherapeuticsNCT06305910